MaxCyte, Inc. (NASDAQ:MXCT) Short Interest Update

MaxCyte, Inc. (NASDAQ:MXCT) saw a large growth in short interest in the month of February. As of February 13th, there was short interest totaling 5,092,073 shares, a growth of 31.2% from the January 29th total of 3,881,689 shares. Based on an average trading volume of 1,727,932 shares, the days-to-cover ratio is currently 2.9 days. Currently, 4.9% of the company’s shares are sold short. Currently, 4.9% of the company’s shares are sold short. Based on an average trading volume of 1,727,932 shares, the days-to-cover ratio is currently 2.9 days.

Wall Street Analysts Forecast Growth

MXCT has been the topic of a number of research analyst reports. Wall Street Zen raised MaxCyte from a “sell” rating to a “hold” rating in a report on Saturday, February 7th. Weiss Ratings restated a “sell (e+)” rating on shares of MaxCyte in a report on Monday, December 29th. Two investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $7.00.

MaxCyte Stock Performance

MaxCyte stock traded down $0.02 during midday trading on Monday, hitting $0.79. 1,054,866 shares of the company were exchanged, compared to its average volume of 1,436,582. The firm has a market capitalization of $84.07 million, a PE ratio of -1.79 and a beta of 1.22. The business has a fifty day simple moving average of $1.11 and a two-hundred day simple moving average of $1.40. MaxCyte has a fifty-two week low of $0.64 and a fifty-two week high of $3.58.

Hedge Funds Weigh In On MaxCyte

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. CWM LLC boosted its holdings in MaxCyte by 92.7% in the second quarter. CWM LLC now owns 12,132 shares of the company’s stock valued at $26,000 after purchasing an additional 5,836 shares during the period. BNP Paribas Financial Markets increased its stake in shares of MaxCyte by 39.5% during the third quarter. BNP Paribas Financial Markets now owns 36,271 shares of the company’s stock worth $57,000 after buying an additional 10,263 shares during the period. Kwmg LLC raised its holdings in MaxCyte by 75.8% in the third quarter. Kwmg LLC now owns 25,833 shares of the company’s stock valued at $41,000 after acquiring an additional 11,135 shares in the last quarter. Prudential Financial Inc. purchased a new position in MaxCyte in the second quarter worth approximately $26,000. Finally, State of Wyoming acquired a new position in MaxCyte during the 2nd quarter worth approximately $38,000. Institutional investors and hedge funds own 68.81% of the company’s stock.

MaxCyte Company Profile

MaxCyte, Inc (NASDAQ: MXCT) is a clinical‐stage cell therapy platform company that develops and commercializes proprietary flow electroporation technology for the delivery of macromolecules into living cells. The company’s instruments and consumables are designed to support research, preclinical development and clinical‐scale manufacturing of cell therapies across a variety of modalities, including engineered T cells, natural killer (NK) cells and induced pluripotent stem cell (iPSC) therapies.